CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
28 results
Search Results
Now showing 1 - 10 of 28
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Copper-Modified Cellulose Paper: A Comparative Study of How Antimicrobial Activity Is Affected by Particle Size and Testing Standards(MDPI AG, 2025-01-08) ;Sara Ramírez ;Fabian Zúñiga ;Alejandra Amenábar; Viviana BenavidesThis study aims to provide evidence that when testing cellulose paper modified with copper particles (CuPs), the particle size and the analysis method influence the antimicrobial activity observed by this material. Commercial CuPs of nanometric size (2.7 nm, CuNPs) and micrometric size (2.5 µm, CuMPs) were used to modify cellulose paper sheets. CuPs were incorporated during the pulp disintegration phase (stage 1) of the sheet formation process, according to the ISO 5269-1:2005 standard. Modified paper sheets retained 16% and 14% of CuNPs and CuMPs, respectively. Additionally, CuPs were distributed randomly on the fiber surfaces, often forming aggregates. Finally, the antimicrobial activity of the modified paper sheets was evaluated using ISO 20645:2004 and ISO 20743:2013. The results showed that the antimicrobial activity assessed using each standard method is conditioned by the mechanism of action of the CuPs and, therefore, by their size. It was concluded that ISO 20645:2004 is suitable for evaluating the antibacterial effect of paper/CuNPs, as nanoparticles diffuse from the paper and are released into the culture medium. In contrast, ISO 20743:2013 can be used for both CuNP- and CuMP-based paper, as it evaluates the antibacterial effect based on the direct interaction between the copper particle and the bacteria.Scopus© Citations 2 14 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Performance of the VITEK® MS system for the identification of filamentous fungi in a microbiological laboratory in Chile(Public Library of Science (PLoS), 2024-12-23); ;Rodrigo Cruz ;Pérez Villa, Inia ;Carmen VarelaCristina Díaz<jats:p>Filamentous fungi are an emergent cause of severe infections in immunocompromised patients. Timely and accurate identification is crucial to initiate appropriate therapy. Traditional identification methods are time-consuming, labor-intensive, and operator-dependent. Matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry is a rapid and easy-to-perform identification method. The effectiveness of a commercial MALDI-TOF MS platform to identify filamentous fungi in a clinical laboratory was evaluated. The study included 67 fungal isolates from 35 species/species complexes, which were identified and confirmed in mycology reference laboratories; 32 derived from clinical samples, 34 from strain collections and one was an ATCC strain. The study used the VITEK<jats:sup>®</jats:sup> MS system (v3.2.0 database), after sample extraction by VITEK<jats:sup>®</jats:sup> MS Mould Kit. Results were classified as “correct species”, “correct species complex”, “correct genus”and “no identification”. VITEK<jats:sup>®</jats:sup> MS correctly identified 91.0% of isolates (58.2% to species, 29.9% to species complex, and 1.5% to genus level only). In 82%, the result matched the species/species complex identified by reference methods. No misidentifications were observed. The kit was rapid and easy to use. In conclusion, the VITEK<jats:sup>®</jats:sup> MS system showed a high capability to accurately identify filamentous fungi in a clinical laboratory.</jats:p>1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections(2024) ;Angelique E Boutzoukas ;Natalie Mackow ;Abhigya Giri ;Lauren KomarowCarol Hill<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P &lt; 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P &lt; 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%–64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P &lt; 0.001].</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.</jats:p> </jats:sec>Scopus© Citations 1 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Editorial: Immune response to gram-negative bacteria in the lungs(2024) ;Agnes Jara-Collao; ;William BainHernán F. Peñaloza - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Excess burden of antibiotic-resistant bloodstream infections: evidence from a multicentre retrospective cohort study in Chile, 2018–2022(2024) ;Kasim Allel ;Anne Peters ;Hassan Haghparast-Bidgoli ;Maria Spencer-SandinoJose ConejerosScopus© Citations 2 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, <i>Venus antiqua</i> Clamshell-Derived Calcium Oxide Nanoparticles for the Preparation of PLA/<scp>d</scp>-Limonene/CaO Nanocomposites with Antimicrobial Properties(2023) ;Viviana Moreno-Serna ;Claudio Oyarzún ;Maria T. Ulloa-Flores; Francesca Antonella SepúlvedaScopus© Citations 17 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multiple clonal transmissions of clinically relevant extended-spectrum beta-lactamase–producing Escherichia coli among livestock, dogs, and wildlife in Chile(2023) ;Juliette Hayer ;Marília Salgado-Caxito ;Andrés Opazo-Capurro ;Paulina González MuñozJavier MillánScopus© Citations 16 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Lives lost and disease burden related to antimicrobial resistance in the Americas can no longer be ignored(2023) ;Eduardo A. Undurraga ;Anne Peters ;Cesar A. Arias2Scopus© Citations 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Head-to-head comparison of CAMPYAIR aerobic culture medium versus standard microaerophilic culture for Campylobacter isolation from clinical samples(2023) ;Arturo Levican ;Carmen Varela; ; Isabel Briceño<jats:p><jats:italic>Campylobacter</jats:italic> spp. are considered the most frequent cause of acute gastroenteritis worldwide. However, outside high-income countries, its burden is poorly understood. Limited published data suggest that <jats:italic>Campylobacter</jats:italic> prevalence in low- and middle-income countries is high, but their reservoirs and age distribution are different. Culturing <jats:italic>Campylobacter</jats:italic> is expensive due to laboratory equipment and supplies needed to grow the bacterium (e.g., selective culture media, microaerophilic atmosphere, and a 42°C incubator). These requirements limit the diagnostic capacity of clinical laboratories in many resource-poor regions, leading to significant underdiagnosis and underreporting of isolation of the pathogen. CAMPYAIR, a newly developed selective differential medium, permits <jats:italic>Campylobacter</jats:italic> isolation without the need for microaerophilic incubation. The medium is supplemented with antibiotics to allow <jats:italic>Campylobacter</jats:italic> isolation in complex matrices such as human feces. The present study aims to evaluate the ability of the medium to recover <jats:italic>Campylobacter</jats:italic> from routine clinical samples. A total of 191 human stool samples were used to compare the ability of CAMPYAIR (aerobic incubation) and a commercial <jats:italic>Campylobacter</jats:italic> medium (CASA, microaerophilic incubation) to recover <jats:italic>Campylobacter</jats:italic>. All <jats:italic>Campylobacter</jats:italic> isolates were then identified by MALDI-TOF MS. CAMPYAIR showed sensitivity and specificity values of 87.5% (95% CI 47.4%–99.7%) and 100% (95% CI 98%–100%), respectively. The positive predictive value of CAMPYAIR was 100% and its negative predictive value was 99.5% (95% CI 96.7%–99.9%); Kappa Cohen coefficient was 0.93 (95% CI 0.79–1.0). The high diagnostic performance and low technical requirements of the CAMPYAIR medium could permit <jats:italic>Campylobacter</jats:italic> culture in countries with limited resources.</jats:p>Scopus© Citations 3 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Chromosome-Mediated Colistin Resistance in Clinical Isolates of Klebsiella pneumoniae and Escherichia coli: Mutation Analysis in the Light of Genetic Background(2023) ;María Paz Riquelme; ;Bárbara Brito ;Patricia GarcíaScopus© Citations 4 2
- «
- 1 (current)
- 2
- 3
- »